Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) (MICCHADO)
Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family of Tumors
About this trial
This is an interventional other trial for Neuroblastoma
Eligibility Criteria
Inclusion Criteria:
- Inclusion within 3 months after diagnosis
- Availability of a cryopreserved tumour sample (primary and/or metastatic and/or lymph nodes) or peripheral blood or bone marrow samples (if invasion more than 30% of lymphoblasts) for leukaemias, obtained at the time of diagnosis during a routine procedure
- Availability of a formalin-fixed paraffin-embedded (FFPE) tumour sample (primary and/or metastasis and/or lymph nodes), obtained at the time of diagnosis during a routine procedure (except for leukaemia patients)
- Age: ≤ 25 years at diagnosis
- Written patient informed consent, or parents or legal representative written informed consent and assent of the child and the adolescent
Compulsory affiliation to a social security scheme
Additional inclusion criteria for the study:
To avoid multiple sampling for children, adolescents and young adults with cancer, patients already included or to be included in a study with similar analyses and/or objectives might also be included in MICCHADO study and in this case, samples or data might be exchanged on a collaborative basis.
Cohort 1:
High risk neuroblastoma:
- Any type of neuroblastoma with MYCN amplification, except INSS stage 1
- Stage 4 neuroblastoma in children older than one year at diagnosis
High risk rhabdomyosarcoma:
- Foxo1 rearrangement any stage;
- and / or N1 ;
- and / or metastatic rhabdomyosarcoma
High risk Ewing sarcoma:
- Metastatic Ewing sarcoma family of tumours (ESFT)
- Localised inoperable Ewing sarcoma with primary tumours ≥ 200 ml
High risk osteosarcoma:
- Metastatic osteosarcoma
- Localised inoperable osteosarcoma
High risk leukaemia:
- Secondary acute myeloid leukaemia
- Biphenotypic acute leukaemia
Cohort 2:
• Extra cerebral or cerebral high risk tumours including:
- other metastatic sarcomas,
- other rare high risk cancers,
- high risk renal tumours with surgery after an initial chemotherapy
- rhabdoid brain tumours (AT/RT) and extra cerebral rhabdoid tumours
- high risk or metastatic cancers of unclear histological diagnosis • Lymphoblastic leukaemia with high MRD at Day 78 (time point 2) • Very high risk T-cells acute lymphoblastic leukaemia:
- MRD ≥ 10-2 at the end of the induction ;
- or MRD ≥ 10-3 at Day 78
Cohort 3:
Children, adolescents and young adults, with low/intermediate risk cancers belonging to the following types:
• Neuroblastoma:
- Localised, without MYCN amplification
- Localised, INSS stage 1, with MYCN amplification
Stage 4s, in infants (younger than one year at diagnosis), without MYCN amplification
• Rhabdomyosarcoma:
Localised, without Foxo1 rearrangement
• ESFT:
- All non-high risk localised ESFT • Osteosarcoma:
- All non-high risk localised osteosarcoma
Exclusion Criteria:
Main non-inclusion Criteria common to all study cohorts:
1) Age: patients > 25 years old at diagnosis 2) Absence of patient or parents or legal representative written informed consent 3) Patient for whom follow-up by the investigating centre does not appear feasible
Sites / Locations
- Chu D'Amiens Picardie
- CHU AngersRecruiting
- CHRU de Besançon - Hôpital Jean-Minjoz
- CHU de Bordeaux - Hôpital des enfants - Groupe Hospitalier PellegrinRecruiting
- CHRU de BrestRecruiting
- CHU CAENRecruiting
- Centre Régional de Cancérologie et Thrapie Cellulaire Pdiatrique (CRCTCP)Recruiting
- CHU Hôpital d'Enfants
- CHU GRENOBLE Alpes - Hôpital Couple-EnfantRecruiting
- Centre Oscar LambretRecruiting
- CHU de Limoges - Hôpital Mère-Enfant
- Centre Léon BérardRecruiting
- Hospices Civils de Lyon
- Hôpital d'Enfants de la Timone (AP-HM)Recruiting
- CHU Arnaud de VilleneuveRecruiting
- CHU Nantes - Hôpital Mère Enfant
- Hôpital l'Archet 2Recruiting
- Hôpital d'Enfants Armand-TrousseauRecruiting
- Hôpital universitaire Robert-Debré (AP-HP)Recruiting
- Institut CurieRecruiting
- CHU de PoitiersRecruiting
- CHU de Reims - Hôpital Américain
- Chu Hopital Sud RennesRecruiting
- CHU de Rouen - Hôp. Charles NICOLLERecruiting
- CHU Saint-Etienne - Hôpital Nord
- Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
- CHU Hôpital des EnfantsRecruiting
- CHU TOURS - Hôpital ClochevilleRecruiting
- CHU Nancy - Hôpital d'EnfantsRecruiting
- Gustave RoussyRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
High risk Cohorts
Low risk Cohort
Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid
Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid